UPDATE: RBC Capital Starts BELLUS Health Inc. (BLU) at Outperform

RBC Capital analyst Gregory Renza initiates coverage on BELLUS Health Inc. (NASDAQ: BLU) with a Outperform rating and a price target of $80.00.

The analyst comments "We see BLU’s lead asset BLU-5937 as a potential first-line therapeutic option in refractory chronic cough (RCC), a patient population in need of therapeutic attention. Despite clinical setbacks, we believe BLU has identified a suitable clinical strategy for BLU-5937 and a demonstrated POC in sub-populations, which, along with differentiation on favorable tolerability, places BLU in a competitive position among an evolving landscape that is worth watching. If successful, we see over $900M out-year WW sales potential with additional upside from prospects of label expansion."

For an analyst ratings summary and ratings history on BELLUS Health Inc. click here. For more ratings news on BELLUS Health Inc. click here.

Shares of BELLUS Health Inc. closed at $3.13 yesterday.

You May Also Be Interested In

• Stifel Starts Arrowhead Pharma (ARWR) at Buy
• MasTec (MTZ) PT Raised to $470 at TD Cowen
• BMO Capital Starts RXO, Inc. (RXO) at Outperform, 'Well Positioned To Leverage TL Market Tightening'